Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TPST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TPST — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On [August 13], 2026, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and other business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including Exhibit 99.1 hereto) is being furnished under “
Why it matters: Good interim data would show that TPST-2003 may help treat multiple myeloma.
Supportive ifInterim data shows a 100% complete response rate among CAR-T-naïve patients treated with TPST-2003.
Worry ifInterim data shows a big drop in response rates or safety issues.
Why it matters: This is a key milestone for Tempest's lead CAR-T candidate. It signals progress in clinical development.
Supportive ifFirst patient dosing of TPST-4003 occurs as planned in Q4 2026.
Worry ifFirst patient dosing is delayed beyond Q4 2026.
Why it matters: News about this partnership may show how TPST-4003 is developing in China.
Watch forSenlang Biotechnology shares news on the TPST-4003 trial in China.
Also watch forNo news or problems are reported about the partnership or trial.
Why it matters: Updates on financial performance will show how the company handles leadership changes. This can change how investors feel.
Watch forFinancial performance shows key metrics improving after the CFO change.
Also watch forFinancial performance metrics get worse or stay the same after the change.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$234 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $953 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,276 loss on $10,000 · 92.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Completing this study is crucial for potential market approval. It shows progress in Tempest's pipeline.
Supportive ifThe study for TPST-2003 is done as planned.
Worry ifThe study for TPST-2003 is late or has not started.
Why it matters: If healthcare revenue growth speeds up, it may benefit Tempest and improve its market position.
Supportive ifHealthcare revenue growth is speeding up again, nearing 10% year over year.
Worry ifHealthcare revenue growth keeps slowing down below current levels.
Why it matters: Initial data will show how safe and effective TPST-4003 is. This could change how investors feel.
Supportive ifInitial clinical data from TPST-4003 is released in the first half of 2027.
Worry ifInitial clinical data is not released by mid-2027.
Why it matters: Good results from TPST-2003 trials can prove Tempest's CAR-T technology. This may bring more investment.
Supportive ifTPST-2003 trials report a sustained 100% complete response rate among treated patients.
Worry ifResponse rates fall below 100% or show safety problems.
Why it matters: The new CFO's plan will show how Tempest will manage finances after the transition. This can impact investor confidence.
Supportive ifA press release detailing the new CFO's strategic financial plan within three months.
Worry ifThe new CFO has not shared any news about financial plans.
Why it matters: Fixing compliance issues is important for Tempest to keep its listing and investor trust.
Supportive ifTempest gets confirmation that it meets Nasdaq listing rules.
Worry ifTempest fails to resolve compliance issues and faces delisting.
Why it matters: News on partnerships can show Tempest's growth and market strength. New deals may improve their pipeline.
Supportive ifTempest announces new partnerships or deals that grow its CAR-T pipeline.
Worry ifNo new partnerships are announced, or current ones end.